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A B S T R A C T
Chagas disease, caused by the parasite Trypanosoma cruzi, is one of the most neglected diseases in Latin America,
being currently a global health problem. Its immunopathogenesis is still quite unknown. Moreover, there are
important differences in pathogenicity between some different T. cruzi strains. For example, in mice, Y strain
produces a high acute lethality while VFRA remains in the host mostly in a chronic manner.
Comparative proteomic studies between T. cruzi strains represent a complement for transcriptomics and may
allow the detection of relevant factors or distinctive functions. Here for the first time, we compared the proteome
of trypomastigotes from 2 strains, Y and VFRA, analyzed by mass spectrometry. Gene ontology analysis were
used to display similarities or differences in cellular components, biological processes and molecular functions.
Also, we performed metabolic pathways enrichment analysis to detect the most relevant pathways in each strain.
Although in general they have similar profiles in the different ontology groups, there were some particular
interesting differences. Moreover, there were around 10% of different proteins between Y and VFRA strains, that
were shared by other T. cruzi strains or protozoan species. They displayed many common enriched metabolic
pathways but some others were uniquely enriched in one strain. Thus, we detected enriched antioxidant defenses
in VFRA that could correlate with its ability to induce a chronic infection in mice controlling ROS production,
while the Y strain revealed a great enrichment of pathways related with nucleotides and protein production, that
could fit with its high parasite replication and lethality. In summary, Y and VFRA strains displayed comparable
proteomes with some particular distinctions that could contribute to understand their different biological be-
haviors.
1. Introduction
Trypanosoma cruzi is the etiological agent of Chagas disease or
American Trypanosomiasis, a chronic endemic illness of Latin America,
and a neglected tropical disease (World Health Organization Chagas
disease (American trypanosomiasis), 2019). In endemic areas, vectorial
transmission is the most common way to get infected, while blood and
organ transplantation transmission are becoming a health problem in
some non-endemic countries due to immigration (Bern et al., 2007;
Schmunis and Yadon, 2010). Nowadays, it has been estimated that
there are around 6–7 million of chronically infected people (World
Health Organization Chagas disease (American trypanosomiasis),
2019).
T. cruzi life cycle is very complex, involving an invertebrate hema-
tophagous triatomine as principal vector (Clayton, 2010). In the
digestive tract of triatomines they have the non-infective epimastigotes
and in the final portion of the intestine the infective metacyclic try-
pomastigotes. Infection of mammals occurs when they come into con-
tact with the infective metacyclic forms of the parasite that are elimi-
nated with the feces of triatomines. After the infection of host cells T.
cruzi differentiates to the intracellular replicative amastigotes, that after
several rounds of intracellular replication they lyse the cell and escape
as bloodstream trypomastigotes and the cycle continues (de Souza
et al., 2010; De Souza, 2002; Rodrigues et al., 2014). Chagas disease
presents three clinical phases (Rassi Jr. et al., 2012). Acute phase with
low mortality and symptomatology, asymptomatic chronic phase for
years or for life, and clinical chronic phase in which 30–40% of the
patients will present after 10–30 years a chronic myocarditis, mega-
visceras or both. Nowadays, there are only two drugs (Nifurtimox and
Benznidazole) with questioned efficacy in chronically infected adults
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and having many adverse effects (Bermudez et al., 2016; Muller Kratz
et al., 2018; Sales Junior et al., 2017).
T. cruzi presents a huge genomic variability (Reis-Cunha et al.,
2015; Callejas-Hernandez et al., 2018), and 6 different “discrete typing
units” (DTU) named from TcI to TcVI (Zingales et al., 2009) have been
described. This classification has been established based on some con-
served genetic sequences (genomic and mitochondrial DNA). A poten-
tial seventh DTU (Tcbat) (Marcili et al., 2009; Zingales et al., 2012) was
described in bats and with subsequent studies based on diverse mole-
cular markers it has been described as a seventh DTU (Lima et al.,
2015). It has been proposed that both the parasite and host genetic
variability may be the causes of differential clinical manifestations of
the disease (Zingales et al., 2012), (Manoel-Caetano Fda and Silva,
2007). The parasite can invade many nucleated cells of the human
body, although it infects more frequently macrophages, dendritic cells
(DCs) and cardiomyocytes (Campbell et al., 2004; Teixeira et al., 2006;
Gil-Jaramillo et al., 2016).
T. cruzi strains highly differ in pathogenicity. Some are acute lethal
strains as Y, whereas others, such as VFRA, produce a chronic infection
in BALB/c mice (Rodriguez et al., 2014). Mice infected with Y strain die
after 30 days, while the mice infected with VFRA survive for months.
Furthermore, Y strain produces higher levels of parasitemia and more
replication rates in macrophages and heart than VFRA strain.
Transcriptomic and proteomics studies have been performed to
understand the changes at a molecular level that could explain the
differences that are observed in the infection models. There are pro-
teomes of different T. cruzi strains available in the public databases.
However, most of these proteomes are product of in silico genome
translations. Only a few publications about T. cruzi proteomes were
studied by mass spectrometry and most of them comparing different
parasite stages (Atwood 3rd et al., 2005; Avila et al., 2018; Bayer-
Santos et al., 2013; de Godoy et al., 2012; Brunoro et al., 2015; Ribeiro
et al., 2018; Queiroz et al., 2013). One of the first studies analyzed the
different life-cycle stages of CL-Brener strain (Atwood 3rd et al., 2005),
showing apparently distinct energy sources between them, as carbo-
hydrates and lipids for trypomastigotes and amastigotes forms, or his-
tidine in the insect vector. The proteomes of metacyclogenesis in
Dm28c epimastigotes has also been performed to determine how the
expression of specific proteins change in this process (de Godoy et al.,
2012). Other researchers focused on specific forms of the parasite such
as the CL-Brener epimastigotes in the exponential and stationary
growth phases (Avila et al., 2018), showing a regulation of proteins
involved in different subcellular compartments or metabolic pathways
such as glycolysis, whereas others focused on establishment of the
bloodstream trypomastigotes proteome of Y strain (Brunoro et al.,
2015). Not only total proteomes have been established, specific cell
surface proteome of the parasite has been previously analyzed, adding
new previously undetected proteins to the parasite proteomes (Queiroz
et al., 2013). Also, the secretome of extracellular vesicles of different
strains have been studied (Bayer-Santos et al., 2013; Ribeiro et al.,
2018) supporting the notion that T. cruzi uses different secretion
pathways to excrete/secrete particular proteins. However, comparisons
between strains have not been performed extensively and this should
allow discovering strain-specific differences that could explain their
distinctions in their pathogenicity.
In this work, we focused for the first time on the comparative
analysis between trypomastigote proteomes of Y and VFRA strains,
because of their different immunopathogenic behavior in mice
(Rodriguez et al., 2014). We performed gene ontology and metabolic
pathway enrichment analysis to understand in a global way the prin-
cipal functions, processes or pathways that are representative of each
strain.
2. Materials and methods
2.1. Parasite culture and isolation
Y T. cruzi strain was obtained from Dr. David (Harvard Medical
School, Boston, MA, USA) and VFRA strain from ChagasEpiNet VII
Framework Consortium. Vero cells (African green monkey kidney,
ATCC) were grown in RPMI medium supplemented with 5% fetal bo-
vine serum (FBS), 100 UI/mL of antibiotics mixture, 10μg/mL strep-
tomycin (Streptomycin Sulfate BioChemica, PanReac AppliChem) and
2mM L-glutamine (Merck) at 37°C in an atmosphere of 5% CO2 until
the cells reached 80% confluence. The cell monolayer was subsequently
infected with metacyclic trypomastigotes (VFRA and Y, 10 parasites per
cell). After 4 days, the supernatant medium was collected.
Trypomastigotes were obtained from these Vero cell co-cultures by
differential centrifugation at 1000 g for 5min to eliminate the amasti-
gotes and dead cells and centrifugation at 1600 g for 10min to isolate
them.
2.2. Protein extraction and digestion
Parasites were lysed in lysis buffer (50mM Tris-HCl pH 7.5, 150mM
NaCl, 2mM EDTA, 1mM EGTA, 1% Triton X-100) in the presence of
protease (Complete tablets Easypack, Roche) and phosphatase in-
hibitors (PhosSTOP, Roche) following the provider's instructions. In the
case of protease inhibitors, a double amount was used due to the high
rate of expression of proteases by the parasites. Protein concentrations
were determined by the Bicinchoninic acid assay (BCA Protein Assay,
Thermo Scientific) using an extrapolation on a standard curve of known
concentrations of Bovine Serum Albumin (BSA). Then, a 1D-gel con-
taining 500 μg of each sample was run to concentrate proteins and
stained with the Colloidal Blue Staining Kit (Invitrogen) for protein
visualization. We obtained a high protein concentration, therefore the
spots of maximum protein concentration were automatically excised
using a ProteomeWorks Spot Cutter (Bio-Rad), separated in smaller
fractions and subjected to manual tryptic digestion (Cristobo et al.,
2011). Destaining of the gel pieces was done first with 50mM ammo-
nium bicarbonate (Sigma-Aldrich) and second with acetonitrile (ACN)
(Scharlau). Proteins were reduced with 10mM dithiothreitol (Sigma-
Aldrich) at 56 °C for 30min. Prior to digestion, proteins were alkylated
replacing the previous solution with 40mM iodoacetamide (Sigma-Al-
drich) and incubating at room temperature for 60min in the dark. For
the digestion, 12.5 ng/μL of trypsin (Promega) in 50mM ammonium
bicarbonate solution was added to the gel pieces for 8 h at 37 °C. Fi-
nally, peptide extraction was performed adding 70% ACN containing
0.5% trifluoroacetic acid (TFA) (Sigma-Aldrich). Tryptic eluted pep-
tides were dried by speed-vacuum centrifugation and resuspended in
4 μL of 30% ACN - 0.1% TFA. One μL of each peptide mixture was
deposited onto an 800 μm AnchorChip (Bruker-Daltonics) and dried at
room temperature. One μL of matrix solution (3mg/mL α-cyano-4-hy-
droxycinnamic acid) in 33% ACN - 0.1% TFA was deposited onto the
digest and allowed to dry at room temperature. Two biological re-
plicates and two technical replicates were acquired for each condition.
2.3. NanoLC-MS/MS analysis and protein identification
Samples were analyzed using an EASY-nano LC system (Proxeon
Biosystems) coupled online with an LTQ-Orbitrap Velos mass spectro-
meter (Thermo Scientific). For the chromatographic separation, after
the retention in a precolumn Acclaim PepMap 100 (Thermo Scientific),
peptides were eluted in a column Acclaim PepMap 100 C18, with 25 cm
of length, 75 μm of inner diameter and 3 μm of particle size (Thermo
Scientific). Peptides mixtures were separated using a gradient from
phase A (0,1% formic acid) to 35% phase B (0,1% formic acid in
acetonitrile) for 100min, 35% to 45% phase B for 20min; 45% to 95%
phase B for 5min, 95% phase B for 4min and 0% phase B for 1min. A
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total of 130min with a flow rate of 250 nL/min.
Mass spectra were acquired in positive ion mode by applying a data-
dependent automatic survey MS scan and tandem mass spectra (MS/
MS) acquisition mode. Survey full-scan MS spectra (with a range of
300–1800m/z and a resolution of R=60,000 at m/z=400) were
acquired in the Orbitrap analyzer. After that the 15 most intense ions
were sequentially isolated and fragmented in the LTQ using collision-
induced dissociation (CID) with a normalized collision energy of 35%.
Selected sequenced ions were dynamically excluded for 45 s.
Raw files were searched against a protozoan database of UniProt
(downloaded in August 2018) that contained some of the most re-
presentative and studied strains of T. cruzi such as CL-Brener, Dm28c,
Sylvio X10 and Marinkellei and other related species as Leishmania and
Trypanosoma brucei among others, using Proteome Discoverer (Version
1.4.1.14, Thermo Scientific) with Sequest algorithm.
Carbamidomethylation of cysteines and oxidation of methionines were
set as fixed modifications. Search parameters specified a MS tolerance
of 7 ppm and a MS/MS tolerance of 0,5 Da. Peptide identification was
validated by the algorithm Percolator using a q≤ 0,01 (Kall et al.,
2007) and a minimum peptide length of six amino acids residues.
2.4. Data analysis
Proteins were classified by gene ontology (GO) analysis using
Blast2GO software (Conesa et al., 2005). This tool uses basic local
alignment search tool (BLAST) and InterPro algorithms to associate
possible functions to our detected sequences. Then, the software clas-
sifies the functions along the first three levels of ontology: biological
processes, cellular components and molecular functions identifying the
proteins that belong to each level. BLAST analyses against different T.
cruzi databases of the unique proteins in each strain were performed
with the available tool in the website https://blast.ncbi.nlm.nih.gov/
Blast.cgi establishing a filter of> 90% similarity to consider two pro-
teins as the same protein. For the metabolic pathway enrichment ana-
lysis, we used the TriTrypDB website tools (https://tritrypdb.org/
tritrypdb/) that perform a Fisher's exact test to determine the sig-
nificant pathways with a p-value adjusted using the Benjamini-Hoch-
berg (BH) method to control FDR. Only pathways with FDR equal or
lower than 0.05 were displayed. Venn diagrams were done with the tool
of the Bioinformatics & Evolutionary Genomics (http://bioinformatics.
psb.ugent.be/webtools/Venn/). All the other figures were done using R
program (Version 3.5.1).
2.5. Repository data
The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium (Deutsch et al., 2017) via the PRIDE
(Perez-Riverol et al., 2019) partner repository with the dataset identi-
fier PXD012536.
3. Results and discussion
3.1. Proteomes of trypomastigotes from Y and VFRA T. cruzi strains
We analyzed trypomastigote proteomes by mass spectrometry. For
protein identification from peptide sequences we used a non-redundant
protozoan protein database from UniProt. We detected 6759 different
peptides in the Y strain and 6957 in the VFRA strain. Those peptides can
be ascribed to a total of 2117 proteins in Y strain and 1983 in VFRA
strain (Supplementary Table 1). Since most of the T. cruzi proteins
deduced from the genome correspond to hypothetical proteins of un-
known function (Callejas-Hernandez et al., 2018) is not surprising that
in our proteomes there were 879 hypothetical proteins in Y strain and
749 in VFRA strain (Table 1). We performed BLAST analysis between
the detected proteins in both proteomes, establishing a threshold
in> 90% of similarity to suppose that two proteins are the same. Ac-
cording to this, from the 2117 proteins detected in the Y strain pro-
teome and the 1983 proteins of the VFRA strain proteome, 1820 pro-
teins were shared by both strains. Therefore, about 90% of proteins are
common by both strains and they have around 10% of unique proteins
that could correlate with particular functions or processes of each
strain. Interestingly, among the unique proteins 240 proteins in Y strain
and 106 in VFRA are hypothetical, and each strain has only 57 unique
proteins with a known-function.
3.2. Comparison of trypomastigote proteomes of Y and VFRA strains
With the detected proteomes, a gene ontology (GO) analysis was
performed for each strain by the Blast2GO software, that gives a hier-
archical classification in levels that summarizes the most common on-
tology groups of the original dataset. We compared the results between
strains in the different ontologies through the principal levels that refer
to the most relevant and global processes of the parasite.
3.2.1. Cellular components
In the level 2, the immediate level after the assignment of proteins
to each ontology, there were about 300 proteins in the cell and cell part
groups in both strains, a bit more in Y strain (Fig. 1). Furthermore, there
were about 150 proteins in the membrane, membrane part, organelle and
protein-containing groups. Y strain displayed a bit more proteins in or-
ganelle group, while VFRA presented more proteins in membrane and
membrane part groups. According to GO Consortium terminology, cell
part refers to any constituent part of the cell, and cell includes the same
plus the plasma membrane and external encapsulating structures. The
same applied to other groups such as membrane and membrane part, in
this one we have any constituent of a membrane, and in membrane we
include any protein embedded or attached to it.
Then, we analyzed deeper some of the more relevant groups in the
level 2 attending to the number of proteins and type of sub-groups in
the following third and fourth levels. Sub-groups that represent specific
components of the cell can be visualized in Fig. 2A for Y strain and 2B
for VFRA strain (complete data is shown in Supplementary Fig. S1).
Inside the cell part group, we found some groups with more members in
VFRA than Y strain, such as cell projection and envelope, with around 15
proteins. Respect to the endomembrane system subgroup, there was a
higher number in Y strain, with>25 proteins.
In both strains, there were a lot of intracellular organelles proteins,
but more in Y strain (> 175 proteins). Also, inside the group of protein-
containing complex Y strain displayed more proteins for the ribonu-
cleoprotein and DNA packaging complexes than VFRA strain. All to-
gether suggest that Y strain possess more proteins dedicated to re-
plication, which fits with the higher replication and proliferation of this
strain comparing to VFRA (Rodriguez et al., 2014). Moreover, in the
membrane group both strains displayed> 125 intrinsic components of
membrane, that correlates with other previous proteome studies of
other strains and forms of T. cruzi (Avila et al., 2018; Brunoro et al.,
Table 1
Summary of the number of unique, shared and hypothetical proteins detected in the mass spectrometry in each strain.
Strain Total proteins detected Hypothetical proteins Total proteins shared Total unique proteins Unique proteins with detected function
Y 2117 879 1820 297 57
VFRA 1983 749 1820 163 57
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2015), supporting the relevance of the membrane proteins for this
parasite. Interestingly, we have detected more proteins that belong to
photosynthetic complexes in VFRA than in Y strain. Photosynthetic
processes in trypanosomes are mostly unknown, but some authors have
discovered genes with photosynthetic potential (Hannaert et al., 2003)
and functions of algae or plants in protists as Leishmania major or T.
cruzi (Mulangi et al., 2012; Teich et al., 2007).
3.2.2. Biological processes
Level 2 groups with more members were metabolic and cellular
processes with> 400 proteins followed by localization group with
around 80 proteins in both strains (Fig. 3). In those, together with
biological regulation and multi-organism process groups, VFRA showed a
bit more proteins than Y strain, while in the case of biogenesis, detox-
ification and response to stimulus groups a bit more members were dis-
played in Y than VFRA strain. However, there were not critical differ-
ences in the number of proteins between both strains. Therefore,
generally we can say that these parasites have similar profiles.
Regarding the third and fourth levels for Y (Fig. 4A) and VFRA
strain (Fig. 4B), in metabolic process, the most represented sub-groups
were organic substance, primary, cellular and nitrogen compound metabo-
lism with> 300 proteins. Metabolic process is one of the biological
processes with more detected proteins in the previously described
proteomes of different strains and forms of the parasite (Avila et al.,
2018; Brunoro et al., 2015). Considering the cellular processes, we found
some relevant sub-groups such as cellular component organization and
microtubule-based process with a bit more members in VFRA strain, and
others such as protein folding with a bit more members in Y strain. These
particular sub-groups, together with response to stress, have been de-
tected in previous transcriptomic studies as common high expressed
genes in trypomastigotes (Berna et al., 2017), and our results confirms
their expression in a protein level enhancing their relevance for the
parasite. Also, some of the differences that we found in the level 2 can
be found again, as more proteins in the sub-groups of metabolic processes
in VFRA strain. Globally, both strains display similar profiles con-
sidering the biological process ontology (Supplementary Fig. S2).
3.2.3. Molecular functions
In upper level 2 analysis, we found two groups with> 400 se-
quences: binding and catalytic activity in both strains (Fig. 5), and in both
VFRA displayed more proteins than Y strain, being more evident in the
case of catalytic activity. Those high numbers likely indicate the need of
proteins/enzymes required for a large number of processes and func-
tions. VFRA displayed a bit more proteins for transporter activity and in
the case of structural molecule and antioxidant activity there were more
proteins in Y than VFRA strain, although the differences were minimal.
In the analysis of the third and fourth levels (Fig. 6), there were no
big differences between strains in the sub-groups of binding or catalytic
activity, although a bit more proteins in the case of VFRA strain sub-
groups was observed, which correlates with the previous analysis of the
level 2. Interestingly, the sub-group of drug binding has proteins that
interact with drug compounds that are used for diagnosis, prevention or
treatment, although the final effect of the interaction cannot be in-
ferred. Interestingly, both strains displayed>100 proteins with this
molecular function that has not been detected in other gene ontology
studies of epimastigotes of Dm28c (de Godoy et al., 2012) and CL-
Brener strains (Avila et al., 2018), suggesting their relevance for the
infective trypomastigote form of the parasite. They include many pro-
teasome proteins or ubiquitin enzymes that are being assessed as new
drug targets (Gupta et al., 2018), or proteins for the export of drugs as
different ABC transporters (da Costa et al., 2018; Zingales et al., 2015),
in line with the available information about the drug resistance of T.
organelle part supramolecular complex membrane−enclosed lumen
membrane membrane part protein−containing complex
cell cell part organelle





















Fig. 1. Level 2 of cellular components. Gene ontology enrichments obtained from the Blast2GO software, classified by sequences and ontology groups.
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Fig. 2. Levels 3 and 4 of cellular components. Number of proteins in the sub-groups (levels 3 and 4 in the Blast2GO analysis) of the principal groups (level 2) in the
cellular components ontology. (A) Classification for Y strain. (B) Classification for VFRA strain.
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cruzi (Zingales, 2018).
In the structural molecule group, the subgroup of structural constituent
of the ribosome displayed more members (> 50) in the case of Y strain,
supporting the idea about a better proliferation and protein production
of Y strain respect to VFRA strain (Rodriguez et al., 2014). In the other
groups, the differences among strains were scarce. Therefore, despite
some punctual differences, in the principal levels of molecular functions
ontology both strains display very close profiles (Supplementary Fig.
S3).
Considering all the ontology aspects of the GO analysis, Y and VFRA
strains show comparable compositions. The very similar results in
biological processes and molecular functions represents a logical effect
because they contain critical proteins for the cellular maintenance and
anabolic/catabolic metabolism. However, there were a few differences
that could be strain-specific pointing to differences in biological beha-
vior.
3.2.4. Unique proteins of each strain proteome
Around a 10% of the total identified proteins were unique in each
strain: 297 proteins in Y strain that were not found in VFRA strain and
163 proteins in VFRA strain that were not found in Y strain. However, a
lot of them were hypothetical, 240 in Y and 106 in VFRA. Therefore,
each strain only displayed 57 unique proteins with known-function.
Then, we searched by BLAST the unique proteins in other T. cruzi
strains to detect if there are groups of strains with those proteins. We
used different in silico proteome databases obtained from the previous
genome assemblies of the following strains: Dm28c (Grisard et al.,
2014; Berna et al., 2018), Sylvio X10 (Franzen et al., 2011), CL-Brener
Non-Esmeraldo-like (El-Sayed et al., 2005) and CL-Brener Esmeraldo-
like (El-Sayed et al., 2005). We downloaded the databases from the
Tritrypdb website (https://tritrypdb.org/tritrypdb/).Regarding the 57
Y strain unique proteins, we obtained 42 proteins with more than a 90%
of similarity in other T. cruzi strains. Inside this group, 41 were detected
in Dm28c, 40 in CL-Brener Non-Esmeraldo-like, 36 in CL-Brener Es-
meraldo-like and 20 in Sylvio X10. In the case of the 57 VFRA strain
unique proteins there were 40 proteins with that similarity in other T.
cruzi strains, 39 were detected in Dm28c, 38 in CL-Brener Non-Esmer-
aldo-like, 30 in CL-Brener Esmeraldo-like and 15 in Sylvio X10.
The remaining 15 unique proteins of Y strain and 17 of VFRA strain,
that did not have a similar protein in other T. cruzi strains have, how-
ever, counterparts in other protozoan species. Those results are sum-
marized in a Venn diagram to display the proteins shared with strain Y
(Fig. 7A) or VFRA strain (Fig. 7B). In conclusion, our proteome analyses
have showed small number of proteins not present in all strains of T.
cruzi, with some overlapping among strains, whereas others apparently
unique of Y or VFRA strains are shared with different protozoan species.
detoxification multi−organism process
cellular component 
organization or biogenesis biological regulation response to stimulus
metabolic process cellular process localization


















































Fig. 3. Level 2 of biological processes. Gene ontology enrichments obtained from the Blast2GO software, classified by sequences and ontology groups.
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Fig. 4. Levels 3 and 4 of biological processes. Number of proteins in the sub-groups (levels 3 and 4 in the Blast2GO analysis) of the principal groups (level 2) in the
biological processes ontology. (A) Classification for Y strain. (B) Classification for VFRA strain.
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3.3. Metabolic pathway enrichment analysis displays differences between Y
and VFRA T. cruzi strains
Metabolic pathway enrichment tool performs a Fisher's exact test to
analyze the enrichment or significance of typical pathways in our data
set. We found many similarities, but interestingly, critical differences in
some aspects among strains. The majority of shared enriched metabolic
pathways (Fig. 8A) were related with: a) the replication and growth of
the parasite as different pathways of nitrogen bases or amino acids
biosynthesis, and b) energy production as variations of the TCA cycle
and the succinate/acetate metabolism, Acetyl-CoA metabolism or the
glyoxylate shunt. This last pathway is not found in mammals and it is
important for the parasites because provides malate, a carbon precursor
for anabolic pathways within an environment of nutritional deprivation
(Ginger, 2006). Therefore, the enrichment of the glyoxylate shunt in
both strains supports the fact that it is essential for T. cruzi.
Interestingly, both strains shared the superpathway of ergosterol
biosynthesis, a pathway that generates ergosterol, a characteristic sterol
lipid of fungi and kinetoplastids membranes, being critical for T. cruzi.
In this regard, huge efforts have been devoted to develop a treatment
for Chagas disease using ergosterol biosynthesis inhibitors (Urbina
et al., 2002; Shang et al., 2014; Noguera et al., 2018). Our result sup-
ports the relevance of this pathway as a good drug target for the
parasite since it is enriched in both proteomes.
Regarding the enriched metabolic pathways found uniquely in Y
strain (Fig. 8B), a large number were pathways related with the growth
or replication of the parasite, suggesting a higher replication rate of Y
strain respect to VFRA strain. Some of these metabolic pathways were
those related with the biosynthesis of adenosine nucleotides and ribo-
nucleotides and the 5-phosphoribose 1-diphosphate (PRPP) indicating
the need for an increased nucleotide production. In agreement, other
metabolic pathways as cysteine biosynthesis or purine and pyrimidine
metabolism were also increased. Interestingly, we found that the most
significant metabolic pathway was the mevalonate pathway-I, which
generates isopentenyl diphosphate (IPP), being the principal and sole
source in many organisms of IPP. This mevalonate pathway leads to the
ergosterol biosynthesis-I, another metabolic pathway for the generation
of ergosterol, that surprisingly it is enriched only in Y strain. This may
indicate a higher dependence on the ergosterol by Y strain respect to
VFRA strain.
Also, in contrast to VFRA, Y strain had enriched the UDP-N-acetyl-
glucosamine biosynthesis-I and UDP-glucose biosynthesis, two of the
most important metabolic pathways for the glycosylation modification
and the production of glycoproteins, which are important for the
parasite mediating cellular recognition, host cell adhesion and invasion
and immune evasion (Acosta-Serrano et al., 2001; Giorgi and de
transporter activity antioxidant activity
binding activity catalytic activity structural molecule activity
































Fig. 5. Level 2 of molecular functions. Gene ontology enrichments obtained from the Blast2GO software, classified by sequences and ontology groups.
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Fig. 6. Levels 3 and 4 of molecular functions. Number of proteins in the sub-groups (levels 3 and 4 in the Blast2GO analysis) of the principal groups (level 2) in the
molecular functions ontology. (A) Classification for Y strain. (B) Classification for VFRA strain.
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A
Fig. 7. Venn diagrams of the unique proteins. Number of unique proteins of Y (A) or VFRA (B) strains with a > 90% similarity match in other T. cruzi strains or
protozoan species is displayed. Blue: Dm28c, red: CL-Brener Esmeraldo-like, green: CL-Brener Non-Esmeraldo-like, yellow: Sylvio X10, purple: other protozoan
species. The proteins that belong to each combination are summarized. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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Lederkremer, 2011; Alves and Colli, 2007).
In VFRA, we found more unique enriched metabolic pathways
(Fig. 8C) including a great enrichment in glycolytic routes. Surprisingly,
the gluconeogenesis pathway was also enriched. Curiously, the most
significant metabolic pathways were also related with energy produc-
tion, in particular the fatty acid beta-oxidation, the mitochondrial and
the peroxisomal pathways. The principal role of the degradation of fatty
acids is the generation of Acetyl-CoA for the TCA cycle and the glyox-
ylate shunt, that it is critical for the parasite. Our result may suggest
that fatty acid beta-oxidation is critical for the cellular catabolism and
energy production specifically in VFRA, not being the principal
pathway for this purpose in Y strain.
Finally, other interesting enriched metabolic pathways in VFRA
strain were those related with the antioxidant defenses. VFRA had en-
riched the trypanothione recycling and biosynthesis and two branches
of the pentose phosphate pathway. The trypanothione is a unique thiol
for the elimination of reactive oxygen species (ROS) in trypanosomatids
(Ilari et al., 2017), and the pentose phosphate pathway one of the
principal sources of NADPH, critical for the antioxidant defenses as
electron donor (Kovarova and Barrett, 2016). Moreover, trypanothione
is an essential redox molecule in these parasites because the trypaso-
nomatids have no catalases or peroxide hemoproteins to resist oxidative
stress. This result suggests that VFRA has better antioxidant responses
than Y strain, being more capable to reduce the quantity of ROS in the
host cells. The question is why VFRA and not Y displayed this capability
and if this is related to different biological behaviors in vivo i.e. the
establishment of a chronic infection with VFRA strain. In this regard,
ROS production seemed to be beneficial for the infection of macro-
phages by Y strain (Paiva et al., 2018), and a ROS-derived signal would
be required for parasite proliferation (Goes et al., 2016; Paiva et al.,
2012). Surprisingly, other strains such as Sylvio X10 would have an
opposite behavior (Dhiman and Garg, 2014). On the other hand, the 2
authorized drugs for Chagas disease increase ROS production that may
control the parasite. The presence of more or less antioxidant pathways
may be related to the different sensitivity to those drugs of different T.
cruzi strains. Our proteome results, although highly preliminary, since
they were performed with only 2 strains, may support that ROS meta-
bolism is important for parasite replication and biological behavior,
since a different ROS response seems to occur in VFRA and Y strains
that cause different pathogenicity in mice.
In summary, the high parasite loads and remarkable tissue damage
produced by mouse infection with Y strain (Rodriguez et al., 2014) can
be explained by the conjunction of less antioxidant defenses, that allow
more ROS concentration, and the increase in proliferation. On the other
hand, VFRA does not cause death in mice, generating something very
close to the chronic phase in humans, and had lower proliferation rate
in heart acute infection than Y strain (Rodriguez et al., 2014). This
behavior would fit with our results of the enrichment in trypanothione
metabolism and biosynthesis in VFRA. VFRA would tend to increase
these pathways to cope with the great generation of ROS by NOX2
among other enzymes, producing a better control of its own prolifera-
tion. This likely allows the establishment of a chronic infection.
4. Conclusions
In summary, Y and VFRA proteomes, although they belong to dif-
ferent DTUs, were very similar at the general biological and gene on-
tology levels. Nonetheless, some remarkable differences between Y and
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Fig. 8. Enriched metabolic pathways. Fisher's exact test showing the logarithms
of the p-values. (A) Shared by both strains, VFRA (red) and Y (blue) strains. (B)
Metabolic pathways that were enriched uniquely in Y strain. (C) Metabolic
pathways that were enriched uniquely in VFRA strain. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web
version of this article.)
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VFRA strains were revealed. They uniquely displayed a 10% of specific
known-function proteins that nonetheless were differently shared by
other T. cruzi strains or other protozoan species. Interestingly, VFRA
and Y strains displayed different enriched pathways as antioxidant
defenses or replication protein production respectively, which may
explain their different pathogenicity in the infected hosts. These facts
emphasize the relevance of performing gene ontology and enriched
metabolic pathways analysis for this purpose. This type of comparison
between strains of the parasite had not been performed before, and it
represents a complement for the transcriptomic studies, trying to un-
derstand the distinct compositions and host responses that are observed
in the infection models of T. cruzi.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.meegid.2019.104041.
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